Ratings Summary for VYVANSE
Overall Patient opinion of VYVANSE: 3.4 (satisfied)
(based on 643 reviews ) (updated May 6, 2025)Ratings by Age Group for VYVANSE
Rating Scale from 1 (poor) to 5 (excellent)
| Patient Age Group | Number of Reviews | Average Rating |
|---|---|---|
| Pediatric (Under 18) | 160 | 3.1 |
| Age 18 to 24 | 159 | 3.5 |
| Age 25 to 34 | 116 | 3.5 |
| Age 35 to 44 | 112 | 3.4 |
| Age 45 to 54 | 58 | 3.5 |
| Age 55 to 64 | 27 | 3.8 |
| Age 65 to 74 | 3 | 3.6 |
| Age 75 and up |
Ratings by Sex for VYVANSE
Rating Scale from 1 (poor) to 5 (excellent)
| Patient Sex | Number of Reviews | Average Rating |
|---|---|---|
| Male | 244 | 3.47540983606557 |
| Female | 393 | 3.51908396946565 |
| Not Specified | 4 | 3 |
Would you like to find reviews for VYVANSE taken for a specific reason or resulting in a specific side effect?
Filter Results for VYVANSE
FDA Drug Safety Information for VYVANSE
Check here for Ask a Patient's Adverse Event Summary for VYVANSE based on cases submitted to the FDA. Includes top reasons for taking, adverse events, and major outcomes reported.
VYVANSE (LISDEXAMFETAMINE DIMESYLATE): Lisdexamfetamine is used to treat attention deficit hyperactivity disorder (ADHD) as part of a total treatment plan, including psychological, social, and other treatments. It may help to increase the ability to pay attention, stay focused, and stop fidgeting. Lisdexamfetamine may also be used to treat binge eating disorder (BED). It may help to reduce the number of binge eating days. This medication is a stimulant. It is thought to work by restoring the balance of certain natural chemicals (neurotransmitters) in the brain. This medication is not recommended for use for weight loss due to the risk of serious side effects. FDA Approval Date: 2007-02-23 (Sources: U.S. Centers for Medicare Services, FDA)